BreathePub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0082-2024
Samuel R Wallbanks, Calvin Apen
{"title":"Integration of lung function data: turning snapshots into stories.","authors":"Samuel R Wallbanks, Calvin Apen","doi":"10.1183/20734735.0082-2024","DOIUrl":"https://doi.org/10.1183/20734735.0082-2024","url":null,"abstract":"<p><p>Missing or inaccessible lung function measurements, gathered over time, have the potential to stagnate or impair clinical care decisions being made. This jeopardises patient safety and often contributes to excessive resource utilisation. Data integration is fundamental to clinical decision-making and entails amalgamating lung function data from multiple sources in a user-friendly format. Despite this, current systems for recording lung function data are suboptimal, with copious gaps in the clinical picture arising from missing or inaccessible lung function measurements. This article discusses the importance of data integration for lung function, with a call to action for key stakeholders involved in the performance, management and interpretation of such tests.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240082"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreathePub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0104-2024
Simone Ielo, Andrea Campione, Nicola Leone, Cristiana Bellan, Raffaele Scala
{"title":"Roadside serendipity: an accident can lead to a rare diagnosis.","authors":"Simone Ielo, Andrea Campione, Nicola Leone, Cristiana Bellan, Raffaele Scala","doi":"10.1183/20734735.0104-2024","DOIUrl":"https://doi.org/10.1183/20734735.0104-2024","url":null,"abstract":"<p><p><b>Find out about some of the diagnostic considerations in the field of rare pleural disease</b> https://bit.ly/3xYefzA.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240104"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Controversies in the clinical management of chronic pulmonary aspergillosis.","authors":"Xinxin Hu, Kathryn Hulme, Liana Brien, Sonya Natasha Hutabarat, Zinta Harrington","doi":"10.1183/20734735.0234-2023","DOIUrl":"10.1183/20734735.0234-2023","url":null,"abstract":"<p><p>Chronic pulmonary aspergillosis has a range of manifestations from indolent nodules to semi-invasive infection. Patients may be asymptomatic or have chronic symptoms such as cough and weight loss or present with life-threatening haemoptysis. The physician can choose from a range of available therapies including medical therapy with antifungals, minimally invasive therapy with intracavitary antifungal therapy and surgery involving open thoracotomy or video-assisted thoracoscopic surgery. The patients with the most severe forms of pulmonary infection may not be surgical candidates due to their underlying pulmonary condition. The management of haemoptysis can include tranexamic acid, bronchial artery embolisation, antifungals or surgery. There are few controlled studies to inform clinicians managing complex cases, so a multidisciplinary approach may be helpful.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230234"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreathePub Date : 2024-10-01DOI: 10.1183/20734735.0127-2023
Dávid László Tárnoki, Kinga Karlinger, Carole A Ridge, Fanni Júlia Kiss, Tamás Györke, Elzbieta Magdalena Grabczak, Ádám Domonkos Tárnoki
{"title":"Lung imaging methods: indications, strengths and limitations.","authors":"Dávid László Tárnoki, Kinga Karlinger, Carole A Ridge, Fanni Júlia Kiss, Tamás Györke, Elzbieta Magdalena Grabczak, Ádám Domonkos Tárnoki","doi":"10.1183/20734735.0127-2023","DOIUrl":"10.1183/20734735.0127-2023","url":null,"abstract":"<p><p>Imaging methods are fundamental tools to detect and diagnose lung diseases, monitor their treatment and detect possible complications. Each modality, starting from classical chest radiographs and computed tomography, as well as the ever more popular and easily available thoracic ultrasound, magnetic resonance imaging and nuclear medicine methods, and new techniques such as photon counting computed tomography, radiomics and application of artificial intelligence, has its strong and weak points, which we should be familiar with to properly choose between the methods and interpret their results. In this review, we present the indications, strengths and main limitations of methods for chest imaging.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230127"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreathePub Date : 2024-10-01DOI: 10.1183/20734735.0043-2024
Helen O'Brien, John Murray, Nina Orfali, Ruairi J Fahy
{"title":"Pulmonary complications of bone marrow transplantation.","authors":"Helen O'Brien, John Murray, Nina Orfali, Ruairi J Fahy","doi":"10.1183/20734735.0043-2024","DOIUrl":"10.1183/20734735.0043-2024","url":null,"abstract":"<p><p>Bone marrow transplantation, now often known as haematopoietic stem cell transplantation (HSCT), is a complex choreographed procedure used to treat both acquired and inherited disorders of the bone marrow. It has proven invaluable as therapy for haematological and immunological disorders, and more recently in the treatment of metabolic and enzyme disorders. As the number of performed transplants grows annually, and with patients enjoying improved survival, a knowledge of both early and late complications of HSCT is essential for respiratory trainees and physicians in practice. This article highlights the spectrum of respiratory complications, both infectious and non-infectious, the timeline of their likely occurrence, and the approaches used for diagnosis and treatment, keeping in mind that more than one entity may occur simultaneously. As respiratory issues are often a leading cause of short- and long-term morbidity, consideration of a combined haematology/respiratory clinic may prove useful in this patient population.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240043"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreathePub Date : 2024-10-01DOI: 10.1183/20734735.0224-2023
Irma Mahmutovic Persson, Gracijela Bozovic, Gunilla Westergren-Thorsson, Sara Rolandsson Enes
{"title":"Spatial lung imaging in clinical and translational settings.","authors":"Irma Mahmutovic Persson, Gracijela Bozovic, Gunilla Westergren-Thorsson, Sara Rolandsson Enes","doi":"10.1183/20734735.0224-2023","DOIUrl":"10.1183/20734735.0224-2023","url":null,"abstract":"<p><p>For many severe lung diseases, non-invasive biomarkers from imaging could improve early detection of lung injury or disease onset, establish a diagnosis, or help follow-up disease progression and treatment strategies. Imaging of the thorax and lung is challenging due to its size, respiration movement, transferred cardiac pulsation, vast density range and gravitation sensitivity. However, there is extensive ongoing research in this fast-evolving field. Recent improvements in spatial imaging have allowed us to study the three-dimensional structure of the lung, providing both spatial architecture and transcriptomic information at single-cell resolution. This fast progression, however, comes with several challenges, including significant image file storage and network capacity issues, increased costs, data processing and analysis, the role of artificial intelligence and machine learning, and mechanisms to combine several modalities. In this review, we provide an overview of advances and current issues in the field of spatial lung imaging.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230224"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreathePub Date : 2024-10-01DOI: 10.1183/20734735.0218-2023
Emer Kelly, Richard W Costello
{"title":"Large-scale education in respiratory medicine: content <i>versus</i> delivery.","authors":"Emer Kelly, Richard W Costello","doi":"10.1183/20734735.0218-2023","DOIUrl":"10.1183/20734735.0218-2023","url":null,"abstract":"<p><p>The respiratory literature, both written and in online formats, is growing exponentially. Capturing quality content, to meet the learning needs of those working in all fields of respiratory medicine and delivering it in a palatable, accessible format is challenging but paramount. In this article we discuss ways to determine the information content and review different methods of delivering this content to those who need it.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230218"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreathePub Date : 2024-10-01DOI: 10.1183/20734735.0081-2024
Sachin Ananth, Alexander G Mathioudakis, Jan Hansel
{"title":"Steroids in severe community-acquired pneumonia.","authors":"Sachin Ananth, Alexander G Mathioudakis, Jan Hansel","doi":"10.1183/20734735.0081-2024","DOIUrl":"10.1183/20734735.0081-2024","url":null,"abstract":"<p><p>There is conflicting evidence regarding the use of steroids in severe community-acquired pneumonia (CAP), with previous randomised controlled trials limited by small sample sizes. ESCAPe and CAPE COD are two recently published large trials on steroids in severe CAP. ESCAPe assessed the initiation of methylprednisolone within 72-96 h of hospital admission, while CAPE COD studied the use of hydrocortisone within 24 h of the development of severe CAP. ESCAPe did not show any differences in all-cause 60-day mortality or any of its secondary outcomes. CAPE COD showed that hydrocortisone improved all-cause 28-day mortality and reduced the risk of intubation or vasopressor-dependent shock. Important differences between the trials included the steroid regimens used, timing of steroid administration and baseline characteristics, with more diabetic patients included in ESCAPe. The results of CAPE COD support the initiation of hydrocortisone within 24 h of developing severe CAP, but more research is needed to evaluate long-term outcomes and optimum dosing regimens for steroids in severe CAP.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240081"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreathePub Date : 2024-10-01DOI: 10.1183/20734735.0047-2024
Oke Dimas Asmara, Georgia Hardavella, Sara Ramella, René Horsleben Petersen, Ilona Tietzova, E Christiaan Boerma, Eric Daniel Tenda, Asmaa Bouterfas, Marjolein A Heuvelmans, Wouter H van Geffen
{"title":"Stage III NSCLC treatment options: too many choices.","authors":"Oke Dimas Asmara, Georgia Hardavella, Sara Ramella, René Horsleben Petersen, Ilona Tietzova, E Christiaan Boerma, Eric Daniel Tenda, Asmaa Bouterfas, Marjolein A Heuvelmans, Wouter H van Geffen","doi":"10.1183/20734735.0047-2024","DOIUrl":"10.1183/20734735.0047-2024","url":null,"abstract":"<p><p>Stage III nonsmall cell lung cancer (NSCLC) represents a wide range of tumour (T1 to T4) and nodal (N0 to N3) components, requiring variable management and a multidisciplinary approach. Recent advancements in minimally invasive techniques, molecular biology and novel drug discoveries have accelerated the refinement of stage III NSCLC management. The latest developments in staging include the forthcoming update of the nodal component in the 9th TNM (tumour-node-metastasis) edition, which emphasises the critical role for endobronchial ultrasonography in mediastinal staging. Recent treatment developments include the use of immunotherapy and targeted molecular therapy in both the neoadjuvant and adjuvant setting, either in combination with other modalities or used alone as consolidation. Surgical and radiotherapy advancements have further enhanced patient outcomes. These developments have significantly improved the prognosis for patients with stage III NSCLC. Fast-changing recommendations have also brought about a challenge, with clinicians facing a number of options to choose from. Therefore, a multimodal approach by a multidisciplinary team has become even more crucial in managing stage III NSCLC.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240047"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreathePub Date : 2024-08-27eCollection Date: 2024-06-01DOI: 10.1183/20734735.0039-2024
Tuğbanur Tezvergil, Ismini Kourouni, Adrien E Costantini, Diego Kauffmann-Guerrero, Torsten Gerriet Blum, Thierry Berghmans
{"title":"Stage IV nonsmall cell lung cancer treatment: oligometastatic disease and disease progression, untangling the knot.","authors":"Tuğbanur Tezvergil, Ismini Kourouni, Adrien E Costantini, Diego Kauffmann-Guerrero, Torsten Gerriet Blum, Thierry Berghmans","doi":"10.1183/20734735.0039-2024","DOIUrl":"10.1183/20734735.0039-2024","url":null,"abstract":"<p><p>Stage IV nonsmall cell lung cancer (NSCLC) is a heterogeneous group of patients for whom systemic therapy is decided based on tumour-biological cancer features (histology, PD-L1 expression, genomic alteration, metastatic sites) and patient characteristics (performance status, comorbidities). In most instances, some kind of systemic treatment is proposed, for which immunotherapy-based or targeted therapies are considered the standards of care in 2024. Oligometastatic NSCLC represents a specific concept during the biological spectrum from localised to metastatic disease in which only a limited number of metastatic sites can be documented. Based on this assumption, prospective and a few randomised phase II studies have been performed, which suggested that adding a local ablative treatment to the systemic one can be a new option for selected stage IV NSCLC. The European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO) supported efforts to define oligometastatic NSCLC to unify the semantics within the thoracic oncology community. This article summarises the currently available data and emphasises the questions and perspectives in oligometastatic disease NSCLC in European patient cohorts.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"240039"},"PeriodicalIF":2.3,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}